P110 heptapeptide

P110 heptapeptide is a peptide inhibitor of the Drp1-Fis1 interaction. P110 heptapeptide has anti-inflammatory, immunomodulatory, mitochondrial protective, and neuroprotective activities. Without blocking the physiological functions of Drp1, P110 heptapeptide reduces pathological functions in many models of neurodegeneration, ischemia, and sepsis. P110 heptapeptide can be used for research on neurological and inflammatory diseases[1][2][3].

Product Specifications

CAS Number

[1411976-18-5]

UNSPSC

12352209

Hazard Statement

H302-H315-H319-H335

Target

Dynamin; Reactive Oxygen Species (ROS)

Type

Peptides

Related Pathways

Cytoskeleton; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB

Applications

COVID-19-immunoregulation

Field of Research

Infection; Inflammation/Immunology; Neurological Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/p110.html

Purity

99.13

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

OC(C[C@H](N)C(N[C@@H](CC(C)C)C(N[C@@H](CC(C)C)C(N1[C@@H](CCC1)C(N[C@@H](CCCNC(N)=N)C(NCC(N[C@@H](CO)C(O)=O)=O)=O)=O)=O)=O)=O)=O

Molecular Formula

C32H56N10O11

Molecular Weight

756.85

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

References & Citations

[1]Luis Rios, et al. Targeting an allosteric site in dynamin-related protein 1 to inhibit Fis1-mediated mitochondrial dysfunction. Nat Commun. 2023 Jul 19;14 (1) :4356.|[2]Liu W, et al. Brain-targeted heptapeptide-loaded exosomes attenuated ischemia-reperfusion injury by promoting the transfer of healthy mitochondria from astrocytes to neurons. J Nanobiotechnology. 2022 May 23;20 (1) :242.|[3]Mukherjee R, et al. Drp1/Fis1-Dependent Pathologic Fission and Associated Damaged Extracellular Mitochondria Contribute to Macrophage Dysfunction in Endotoxin Tolerance. Crit Care Med. 2022 Jun 1;50 (6) :e504-e515.